 |
14 Diseases |  |
3 Trials |
|
3 Trials |  |
139 News |  |
| «123» |
- Actemra IV (tocilizumab) / Roche, JW Pharma
[VIRTUAL] The first experience of anti-IL6 administration for COVID-19 infection () - Jul 29, 2021 - Abstract #ERS2021ERS_2124;
122 patients were examined, (59 men and 63 women, age 59.63±10.7 years (31-82 years, ZK-S=1.0; p=0.261), CT1 1.6%, CT2 36, 1%, CT3 54.1%, CT4 8.2% after detection received favipiravir 9.8%, umifenovir 31.1% and its combination with alpha interferon 15.8%, glucocorticosteroids 14.8% and antibiotics 59%...On day 12.11±3.12 (ZK-S=1.26; p=0.1) olokizumab was prescribed (72.1%), tocilizumab (23.8%), levilimab (3.3%) and tocilizumab-olokizumab sequentially (0.8%)... Anti-IL-6 drugs, when administered intravenously, are effective in the treatment of COVID-19, and their effectiveness is higher in the initial stages of desaturation.
- ||||||| Artlegia (olokizumab) - R / Pharm
Trial completion: CREDO 3: Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease (clinicaltrials.gov) - Jul 21, 2021
P3, N=368, Completed, Sponsor: R-Pharm International, LLC
Anti-IL-6 drugs, when administered intravenously, are effective in the treatment of COVID-19, and their effectiveness is higher in the initial stages of desaturation. Active, not recruiting --> Completed
- || olokizumab (CDP-6038) - R / Pharm, Actemra IV (tocilizumab) / Roche, JW Pharma
Clinical, P2 data, Journal: Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies. (Pubmed Central) - Jun 9, 2021
Active, not recruiting --> Completed In the 2 long-term studies, OKZ treatment demonstrated a safety profile expected for IL-6 blocking agents without new safety signals and led to sustained improvements in RA symptoms, physical function, and quality of life.
- olokizumab (CDP-6038) - R / Pharm
[VIRTUAL] “Difficult to treat RA” – definitions and therapeutic prospects: is there a place for olokizumab?” (Industry room 14) - May 31, 2021 - Abstract #EULAR2021EULAR_4167;
In the 2 long-term studies, OKZ treatment demonstrated a safety profile expected for IL-6 blocking agents without new safety signals and led to sustained improvements in RA symptoms, physical function, and quality of life. Sponsored by R-Pharm
- olokizumab (CDP-6038) - R / Pharm
[VIRTUAL] Safety and efficacy of olokizumab in MTX-IR and TNF-IR in CREDO program (Industry room 14) - May 31, 2021 - Abstract #EULAR2021EULAR_4166;
Sponsored by R-Pharm Sponsored by R-Pharm
- olokizumab (CDP-6038) - R / Pharm
[VIRTUAL] R-Pharm - Targeting IL-6 ligand - exploring a novel treatment option with a focus on olokizumab (Industry room 14) - May 31, 2021 - Abstract #EULAR2021EULAR_4164;
Sponsored by R-Pharm. Learning Objectives: Understand IL-6 signaling pathway and differentiate modes of action of various IL-6 inhibitors Evaluate the scientific evidence of direct IL-6 inhibition in patients with moderately to severely active rheumatoid arthritis (efficacy, safety and tolerability based on global phase III studies ) Address the problem of ‘difficult to treat’ patients in RA: current approach and potential strategies Reflect on the modern ways of RA management (EULAR guidelines in clinical practice)
- ||||||| Artlegia (olokizumab) - R / Pharm
Trial completion: CREDO 2: Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (clinicaltrials.gov) - Apr 30, 2021
P3, N=1648, Completed, Sponsor: R-Pharm International, LLC
Learning Objectives: Understand IL-6 signaling pathway and differentiate modes of action of various IL-6 inhibitors Evaluate the scientific evidence of direct IL-6 inhibition in patients with moderately to severely active rheumatoid arthritis (efficacy, safety and tolerability based on global phase III studies ) Address the problem of ‘difficult to treat’ patients in RA: current approach and potential strategies Reflect on the modern ways of RA management (EULAR guidelines in clinical practice) Active, not recruiting --> Completed
- olokizumab (CDP-6038) - R / Pharm
[VIRTUAL] EFFICACY AND SAFETY OF OLOKIZUMAB: RESULTS FROM THE PHASE III RANDOMIZED CONTROLLED TRIAL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS INADEQUATELY CONTROLLED BY TNF INHIBITOR THERAPY (Posters Viewing) - Apr 6, 2021 - Abstract #EULAR2021EULAR_1202;
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Review, Journal: Interleukin-6 blocking agents for treating COVID-19: a living systematic review. (Pubmed Central) - Mar 25, 2021
Thirty-nine RCTs of IL-6 blocking agents with no results are currently registered, of which nine are completed and seven trials were terminated with no results available. The findings of this review will be updated as new data are made available on the COVID-NMA platform (covid-nma.com).
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Antibodies to watch in 2021. (Pubmed Central) - Jan 28, 2021
Despite the pandemic, 10 antibody therapeutics had been granted the first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan...Based on the information publicly available as of November 2020, 44 antibody therapeutics are in late-stage clinical studies for non-cancer indications, including 6 for COVID-19, and marketing applications for at least 6 (leronlimab, tezepelumab, faricimab, ligelizumab, garetosmab, and fasinumab) are planned in 2021...Of these 44, marketing application submissions for 13 may be submitted by the end of 2021. *Note added in proof on key events announced during December 1-21, 2020: margetuximab-cmkb and ansuvimab-zykl were approved by FDA on December 16 and 21, 2020, respectively; biologics license applications were submitted for ublituximab and amivantamab.
- || olokizumab (CDP-6038) - R / Pharm
Clinical, Journal: Analysis of miRNA Expression in Patients with Rheumatoid Arthritis during Olokizumab Treatment. (Pubmed Central) - Nov 5, 2020
The ROC curve analysis of the most prominent of them together with consequent univariate and multivariate regression analysis revealed statistically significant associations with the olokizumab therapy efficiency scores for miR-26b, miR-29, miR-451, and miR-522. Therefore, these miRNAs might be a potential therapeutic response biomarker.
- olokizumab (CDP-6038) - R / Pharm
[VIRTUAL] Olokizumab Improves Patient Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate: Results from the Double-Blind, Randomized Controlled Phase III Study (Feed 10) - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_2775;
P3
Treatment with OKZ over a 24-week period was associated with significant improvements in PRO in patients with moderate to severe RA. There were no discernible differences between the two regimens of OKZ from patient’s perspective.
- ||||||| Artlegia (olokizumab) - R / Pharm, goflikicept (RPH-104) - R / Pharm
Trial completion, Trial completion date: Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19) (clinicaltrials.gov) - Sep 29, 2020
P2/3, N=372, Completed, Sponsor: R-Pharm International, LLC
There were no discernible differences between the two regimens of OKZ from patient’s perspective. Active, not recruiting --> Completed | Trial completion date: Oct 2020 --> Jul 2020
- ||||| Artlegia (olokizumab) - R / Pharm, goflikicept (RPH-104) - R / Pharm
Enrollment closed, Trial primary completion date: Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19) (clinicaltrials.gov) - Sep 16, 2020
P2/3, N=372, Active, not recruiting, Sponsor: R-Pharm International, LLC
Active, not recruiting --> Completed | Trial completion date: Oct 2020 --> Jul 2020 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2020 --> Jul 2020
- ||||| Artlegia (olokizumab) - R / Pharm
Enrollment closed, Trial completion date, Trial primary completion date: CREDO 2: Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (clinicaltrials.gov) - Sep 16, 2020
P3, N=1575, Active, not recruiting, Sponsor: R-Pharm
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2020 --> Jul 2020 Recruiting --> Active, not recruiting | Trial completion date: May 2020 --> Nov 2020 | Trial primary completion date: Dec 2019 --> Sep 2020
- ||||| Artlegia (olokizumab) - R / Pharm
Enrollment closed, Trial completion date, Trial primary completion date: CREDO 3: Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease (clinicaltrials.gov) - Sep 16, 2020
P3, N=350, Active, not recruiting, Sponsor: R-Pharm
Recruiting --> Active, not recruiting | Trial completion date: May 2020 --> Nov 2020 | Trial primary completion date: Dec 2019 --> Sep 2020 Recruiting --> Active, not recruiting | Trial completion date: Jan 2020 --> Dec 2020 | Trial primary completion date: Sep 2019 --> Sep 2020
- olokizumab (CDP-6038) - R / Pharm
[VIRTUAL] Industry-Supported Symposia: Taking the High Road: Olokizumab as a Novel Rheumatoid Arthritis (RA) Treatment Option () - Aug 16, 2020 - Abstract #ACRARHP2020ACR_ARHP_487;
Recruiting --> Active, not recruiting | Trial completion date: Jan 2020 --> Dec 2020 | Trial primary completion date: Sep 2019 --> Sep 2020 Non-CME Developed and offered by R-Pharm
- || Clinical, Journal: Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. (Pubmed Central) - Jul 8, 2020
Non-CME Developed and offered by R-Pharm This SLR informed the task force regarding the evidence base of various therapeutic regimen for the development of the update of EULAR's RA management recommendation.
- |||||||||| Artlegia (olokizumab) - R / Pharm
New P2/3 trial: Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). (clinicaltrials.gov) - Jun 30, 2020
P2/3, N=376, Not yet recruiting, Sponsor: R-Pharm
- olokizumab (CDP-6038) - R / Pharm
[VIRTUAL] OLOKIZUMAB IMPROVES PATIENT REPORTED OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS INADEQUATELY CONTROLLED BY METHOTREXATE: RESULTS FROM THE DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE III STUDY (CREDO-1) (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_3892;
P3
Treatment with OKZ over a 24-week period was associated with significant improvements in PRO in patients with moderate to severe RA. 2.
- | Artlegia (olokizumab) - R / Pharm, goflikicept (RPH-104) - R / Pharm
New P2/3 trial: Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19) (clinicaltrials.gov) - May 8, 2020
P2/3, N=372, Recruiting, Sponsor: R-Pharm International, LLC
- || Artlegia (olokizumab) - R / Pharm
Trial completion date, Trial initiation date, Trial primary completion date: Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4 (clinicaltrials.gov) - Apr 1, 2020
P1, N=15, Not yet recruiting, Sponsor: R-Pharm
2. Trial completion date: Oct 2020 --> Apr 2021 | Initiation date: Mar 2020 --> Jun 2020 | Trial primary completion date: Jun 2020 --> Jan 2021
- olokizumab (CDP-6038) - R / Pharm
[VIRTUAL] OLOKIZUMAB, MONOCLONAL ANTIBODY AGAINST IL6, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS INADEQUATELY CONTROLLED BY METHOTREXATE: EFFICACY AND SAFETY RESULTS OF PHASE III CREDO-1 STUDY (Wollheim) - Mar 4, 2020 - Abstract #EULAR2020EULAR_582;
P3
Treatment with OKZ over a 24-week period was associated with significant improvements in the signs, symptoms and physical function of RA, with a safety profile consistent with Phase II data for OKZ and with the data for the agents with similar mechanism of action. There were no discernible differences between the two regimens of OKZ in efficacy or safety outcomes.
- ||||| Do we need another IL6 inhibitor for rheumatic diseases. Tocilizumab is off patent in USA and Europe. We have Sarilumab but Sirukumab did not go forward in RA. Another kid on block - Olokizumab IL6 receptor blocker with +RA RCT #RWCS2020 @RWCSmtg @RheumNow (Twitter) - Feb 15, 2020
- || Artlegia (olokizumab) - R / Pharm
New P1 trial: Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4 (clinicaltrials.gov) - Jan 29, 2020
P1, N=15, Not yet recruiting, Sponsor: R-Pharm
- olokizumab (CDP-6038) - R / Pharm
Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate - CREDO1 Study (Hall B5) - Oct 19, 2019 - Abstract #ACRARHP2019ACR_4200;
P3
In this Phase III trial, treatment with OKZ over a 24-week period was associated with significant improvements in the signs, symptoms and physical function of RA, with a safety profile consistent with Phase II data for OKZ and with the data for the agents with similar mechanism of action. There were no discernible differences between the two regimens of OKZ in efficacy or safety outcomes.
- olokizumab (CDP-6038) - R / Pharm
Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate - CREDO1 Study (Hall B5) - Oct 19, 2019 - Abstract #ACRARHP2019ACR_4184;
P3
In this Phase III trial, treatment with OKZ over a 24-week period was associated with significant improvements in the signs, symptoms and physical function of RA, with a safety profile consistent with Phase II data for OKZ and with the data for the agents with similar mechanism of action. There were no discernible differences between the two regimens of OKZ in efficacy or safety outcomes.
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Review, Journal: Interleukin-6 inhibition in the management of non-infectious uveitis and beyond. (Pubmed Central) - Sep 17, 2019
In addition, the levels of IL-6 are elevated in other ocular vascular diseases such as retinal vein occlusion and diabetic macular edema. The roles of IL-6 inhibition may be broadened in the future to include the management of retinal vascular diseases and non-uveitic macular edema.
- ||||||| Artlegia (olokizumab) - R / Pharm
Trial completion, Trial completion date, Trial primary completion date: CREDO 1: Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (clinicaltrials.gov) - Dec 3, 2018
P3, N=428, Completed, Sponsor: R-Pharm
The roles of IL-6 inhibition may be broadened in the future to include the management of retinal vascular diseases and non-uveitic macular edema. Recruiting --> Completed | Trial completion date: May 2019 --> Oct 2018 | Trial primary completion date: Jan 2019 --> Aug 2018
- |||||| Artlegia (olokizumab) - R / Pharm
Enrollment open: CREDO 4: Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis (clinicaltrials.gov) - Aug 13, 2017
P3, N=1880, Recruiting, Sponsor: R-Pharm
Recruiting --> Completed | Trial completion date: May 2019 --> Oct 2018 | Trial primary completion date: Jan 2019 --> Aug 2018 Not yet recruiting --> Recruiting
- |||||||||| Artlegia (olokizumab) - R / Pharm
New P3 trial: CREDO 4: Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis (clinicaltrials.gov) - Apr 19, 2017
P3, N=1880, Not yet recruiting, Sponsor: R-Pharm
- |||| Artlegia (olokizumab) - R / Pharm
Trial primary completion date: CREDO 2: Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (clinicaltrials.gov) - Apr 4, 2017
P3, N=1575, Recruiting, Sponsor: R-Pharm
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2019 --> Dec 2019
- |||| Artlegia (olokizumab) - R / Pharm
Trial primary completion date: CREDO 1: Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (clinicaltrials.gov) - Mar 3, 2017
P3, N=420, Recruiting, Sponsor: R-Pharm
Trial primary completion date: Jan 2019 --> Dec 2019 Trial primary completion date: May 2018 --> Jan 2019
- ||||| Artlegia (olokizumab) - R / Pharm
Trial initiation date, Trial primary completion date: CREDO 3: Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease (clinicaltrials.gov) - Mar 3, 2017
P3, N=350, Recruiting, Sponsor: R-Pharm
Trial primary completion date: May 2018 --> Jan 2019 Initiation date: May 2016 --> Dec 2016 | Trial primary completion date: Feb 2019 --> Sep 2019
- |||||| Artlegia (olokizumab) - R / Pharm
Enrollment open: CREDO 2: Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (clinicaltrials.gov) - Dec 19, 2016
P3, N=1575, Recruiting, Sponsor: R-Pharm
Initiation date: May 2016 --> Dec 2016 | Trial primary completion date: Feb 2019 --> Sep 2019 Suspended --> Recruiting
- |||||| Artlegia (olokizumab) - R / Pharm
Enrollment open: CREDO 1: Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (clinicaltrials.gov) - Dec 14, 2016
P3, N=420, Recruiting, Sponsor: R-Pharm
Suspended --> Recruiting Suspended --> Recruiting
- |||||| Artlegia (olokizumab) - R / Pharm
Enrollment open: CREDO 3: Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease (clinicaltrials.gov) - Dec 14, 2016
P3, N=350, Recruiting, Sponsor: R-Pharm
Suspended --> Recruiting Suspended --> Recruiting
- || Artlegia (olokizumab) - R / Pharm
Trial suspension: CREDO 1: Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (clinicaltrials.gov) - Jul 19, 2016
P3, N=420, Suspended, Sponsor: R-Pharm
Suspended --> Recruiting Recruiting --> Suspended
- || Artlegia (olokizumab) - R / Pharm
Trial suspension: CREDO 2: Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (clinicaltrials.gov) - Jul 19, 2016
P3, N=1575, Suspended, Sponsor: R-Pharm
Recruiting --> Suspended Recruiting --> Suspended
- || Artlegia (olokizumab) - R / Pharm
Trial suspension: CREDO 3: Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease (clinicaltrials.gov) - Jul 19, 2016
P3, N=350, Suspended, Sponsor: R-Pharm
Recruiting --> Suspended Recruiting --> Suspended
- |||||| Artlegia (olokizumab) - R / Pharm
Enrollment open: CREDO 1: Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (clinicaltrials.gov) - Jun 1, 2016
P3, N=420, Recruiting, Sponsor: R-Pharm
Recruiting --> Suspended Not yet recruiting --> Recruiting
- |||||| Artlegia (olokizumab) - R / Pharm
Enrollment open: CREDO 2: Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (clinicaltrials.gov) - Jun 1, 2016
P3, N=1575, Recruiting, Sponsor: R-Pharm
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| Artlegia (olokizumab) - R / Pharm
Enrollment open: CREDO 3: Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease (clinicaltrials.gov) - Jun 1, 2016
P3, N=350, Recruiting, Sponsor: R-Pharm
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Artlegia (olokizumab) - R / Pharm
New P3 trial: CREDO 1: Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (clinicaltrials.gov) - May 3, 2016
P3, N=420, Not yet recruiting, Sponsor: R-Pharm
- |||||||||| Artlegia (olokizumab) - R / Pharm
New P3 trial: CREDO 2: Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease (clinicaltrials.gov) - May 3, 2016
P3, N=1575, Not yet recruiting, Sponsor: R-Pharm
- |||||||||| Artlegia (olokizumab) - R / Pharm
New P3 trial: CREDO 3: Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease (clinicaltrials.gov) - May 3, 2016
P3, N=350, Not yet recruiting, Sponsor: R-Pharm
- |||| Artlegia (olokizumab) - R / Pharm
Trial completion: The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis (clinicaltrials.gov) - Dec 15, 2013
P2, N=103, Completed, Sponsor: UCB, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| Artlegia (olokizumab) - R / Pharm
Trial completion: Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056 (clinicaltrials.gov) - Aug 15, 2013
P2, N=190, Completed, Sponsor: UCB BIOSCIENCES, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Artlegia (olokizumab) - R / Pharm
Trial completion: Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy (clinicaltrials.gov) - Feb 28, 2013
P2, N=119, Completed, Sponsor: UCB Japan Co. Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Artlegia (olokizumab) - R / Pharm
Trial withdrawal: A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease (clinicaltrials.gov) - Oct 28, 2012
P2, N=0, Withdrawn, Sponsor: UCB BIOSCIENCES GmbH
Active, not recruiting --> Completed Recruiting --> Withdrawn